HYPOC1
MCID: HYP192
MIFTS: 56

Hypocalcemia, Autosomal Dominant (HYPOC1) malady

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Endocrine diseases

Aliases & Classifications for Hypocalcemia, Autosomal Dominant

About this section

Aliases & Descriptions for Hypocalcemia, Autosomal Dominant:

Name: Hypocalcemia, Autosomal Dominant 52 48 12 50
Autosomal Dominant Hypocalcemia 24 25 54 27 68
Hypocalcemia, Autosomal Dominant 1 52 70 27 68
Autosomal Dominant Hypocalcemia with Bartter Syndrome 70 27
Familial Hypocalcemia 25 70
Hypocalcemia 39 68
Hypocalcemia, Autosomal Dominant, with Bartter Syndrome 52
Hypoparathyroidism - Autosomal Dominant 68
Autosomal Dominant Hypoparathyroidism 25
 
Familial Hypercalciuric Hypocalcemia 25
Bartter Syndrome with Hypocalcemia 54
Hypercalciuric Hypocalcemia 70
Bartter Syndrome Type 5 54
Bartter Syndrome Type V 54
Ad Hypocalcemia 54
Hypoc1 70
Adh 25

Characteristics:

Orphanet epidemiological data:

54
bartter syndrome with hypocalcemia:
Inheritance: Autosomal dominant; Age of onset: Adolescent,Adult,Childhood,Infancy; Age of death: normal life expectancy
autosomal dominant hypocalcemia:
Inheritance: Autosomal dominant; Age of onset: All ages; Age of death: normal life expectancy

HPO:

64
hypocalcemia, autosomal dominant:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM52 601198
ICD10 via Orphanet31 E26.8, E20.8
MeSH39 D006996

Summaries for Hypocalcemia, Autosomal Dominant

About this section
OMIM:52 Autosomal dominant hypocalcemia-1 is associated with low or normal serum parathyroid hormone concentrations (PTH).... (601198) more...

MalaCards based summary: Hypocalcemia, Autosomal Dominant, also known as autosomal dominant hypocalcemia, is related to aneurysm and hypocalcemia, autosomal dominant 2, and has symptoms including muscle cramp, seizures and carpopedal spasm. An important gene associated with Hypocalcemia, Autosomal Dominant is CASR (Calcium Sensing Receptor), and among its related pathways are GPCRs, Class C Metabotropic glutamate, pheromone and Long-term depression. The drugs cod liver oil and calcium carbonate have been mentioned in the context of this disorder. Affiliated tissues include kidney, skin and liver, and related mouse phenotypes are pigmentation and endocrine/exocrine gland.

Genetics Home Reference:25 Autosomal dominant hypocalcemia is characterized by low levels of calcium in the blood (hypocalcemia). Affected individuals can have an imbalance of other molecules in the blood as well, including too much phosphate (hyperphosphatemia) or too little magnesium (hypomagnesemia). Some people with autosomal dominant hypocalcemia also have low levels of a hormone called parathyroid hormone (hypoparathyroidism). This hormone is involved in the regulation of calcium levels in the blood. Abnormal levels of calcium and other molecules in the body can lead to a variety of signs and symptoms, although about half of affected individuals have no associated health problems.

UniProtKB/Swiss-Prot:70 Hypocalcemia, autosomal dominant 1: A disorder of mineral homeostasis characterized by blood calcium levels below normal, and low or normal serum parathyroid hormone concentrations. Disease manifestations include mild or asymptomatic hypocalcemia, paresthesias, carpopedal spasm, seizures, hypercalciuria with nephrocalcinosis or kidney stones, and ectopic and basal ganglia calcifications. Few patients manifest hypocalcemia and features of Bartter syndrome, including hypomagnesemia, hypokalemia, metabolic alkalosis, hyperreninemia, and hyperaldosteronemia.

Related Diseases for Hypocalcemia, Autosomal Dominant

About this section

Diseases in the Hypocalcemia, Autosomal Dominant family:

Hypocalcemia, Autosomal Dominant 2

Diseases related to Hypocalcemia, Autosomal Dominant via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 81)
idRelated DiseaseScoreTop Affiliating Genes
1aneurysm29.2CALCA, PRKAR1A
2hypocalcemia, autosomal dominant 212.3
3inappropriate adh syndrome12.1
4diabetes insipidus, nephrogenic11.7
5syndrome of inappropriate antidiuretic hormone11.2
6bartter disease type 511.2
7hypoparathyroidism, familial isolated11.1
8diabetes insipidus, neurohypophyseal11.0
9hypothalamic disease10.8
10hypohidrotic ectodermal dysplasia, autosomal10.8
11hypoparathyroidism10.2
12cerebrooculofacioskeletal syndrome 410.2CASR, GNA11
13inflammatory bowel disease 610.2CASR, GNA11
14jessner's lymphocytic infiltration of the skin10.2CASR, PRKAR1A
15epilepsy idiopathic generalized 810.2CASR, PRKAR1A
16familial chronic myelocytic leukemia-like syndrome10.2CASR, GNA11
17pseudohypoparathyroidism, type ib10.2GNA11, PRKAR1A
18osseous heteroplasia, progressive10.2GNA11, PRKAR1A
19listeria meningitis10.2CASR, GNA11
20deafness, nonsyndromic, modifier 110.1CASR, VDR
21gastric antral vascular ectasia10.1CASR, VDR
22mitochondrial dna depletion syndrome 610.1CASR, VDR
23cowper gland carcinoma10.1CASR, GCM2
24parathyroid gland disease10.0CASR, GCM2, PRKAR1A
25mesenchymal cell neoplasm10.0CALCA, CASR
26high-grade dysplasia in patients with barrett esophagus10.0CASR, PRKAR1A, VDR
27alcohol dependence10.0
28weill-marchesani syndrome10.0CASR, GCM2, VDR
29epidermolysis bullosa, junctional, herlitz type10.0CALCA, CASR
30acrorenal syndrome9.9CALCA, VDR
31diabetes insipidus9.9
32dentin dysplasia9.9CALCA, VDR
33waardenburg syndrome, type 4b9.9CALCA, CASR, VDR
34pes anserinus tendinitis or bursitis9.8CALCA, CASR, VDR
35tinea unguium9.8CALCA, CASR, VDR
36pre-eclampsia9.8CALCA, CASR, VDR
37indian tick typhus9.8CALCA, CASR, VDR
38lung cancer9.8
39dysbaric osteonecrosis9.8CALCA, VDR
40osteoarthritis9.8
41ischemic bone disease9.7CALCA, VDR
42pancreatic cancer9.7
43brain cancer9.7
44pancreatitis9.7
45pneumonia9.7
46subserous uterine fibroid9.7CALCA, CASR, PRKAR1A, VDR
47opioid abuse9.7CALCA, CASR, GCM2, VDR
48schizophrenia9.6
49colorectal cancer9.6
50myocardial infarction9.6

Graphical network of the top 20 diseases related to Hypocalcemia, Autosomal Dominant:



Diseases related to hypocalcemia, autosomal dominant

Symptoms & Phenotypes for Hypocalcemia, Autosomal Dominant

About this section

Symptoms by clinical synopsis from OMIM:

601198

Clinical features from OMIM:

601198

Human phenotypes related to Hypocalcemia, Autosomal Dominant:

 54 64 (show all 39)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nephrocalcinosis64 54 Frequent (79-30%) HP:0000121
2 optic atrophy64 54 Occasional (29-5%) HP:0000648
3 behavioral abnormality54 Very frequent (99-80%)
4 emotional lability64 54 Very frequent (99-80%) HP:0000712
5 depression64 54 Very frequent (99-80%) HP:0000716
6 anxiety64 54 Very frequent (99-80%) HP:0000739
7 dry skin64 54 Frequent (79-30%) HP:0000958
8 eczema64 54 Occasional (29-5%) HP:0000964
9 abnormality of the fingernails64 54 Frequent (79-30%) HP:0001231
10 alopecia64 54 Frequent (79-30%) HP:0001596
11 abnormality of the nail54 Frequent (79-30%)
12 congestive heart failure64 54 Occasional (29-5%) HP:0001635
13 abdominal pain64 54 Frequent (79-30%) HP:0002027
14 hypercalciuria64 54 Very frequent (99-80%) HP:0002150
15 writer's cramp64 54 Very frequent (99-80%) HP:0002356
16 increased intracranial pressure64 54 Occasional (29-5%) HP:0002516
17 hypotension64 54 Frequent (79-30%) HP:0002615
18 abnormal pattern of respiration64 54 Frequent (79-30%) HP:0002793
19 hypocalcemia64 54 Very frequent (99-80%) HP:0002901
20 hyperphosphatemia64 54 Frequent (79-30%) HP:0002905
21 hypomagnesemia64 54 Frequent (79-30%) HP:0002917
22 paresthesia64 54 Very frequent (99-80%) HP:0003401
23 emg abnormality64 54 Very frequent (99-80%) HP:0003457
24 fatigable weakness64 54 Very frequent (99-80%) HP:0003473
25 reduced bone mineral density64 54 Occasional (29-5%) HP:0004349
26 reduced consciousness/confusion64 54 Occasional (29-5%) HP:0004372
27 irregular hyperpigmentation64 54 Occasional (29-5%) HP:0007400
28 arrhythmia64 54 Frequent (79-30%) HP:0011675
29 hypermagnesiuria64 54 Frequent (79-30%) HP:0012608
30 cortical myoclonus64 54 Very frequent (99-80%) HP:0040148
31 nephrolithiasis64 HP:0000787
32 increased circulating renin level64 HP:0000848
33 seizures64 HP:0001250
34 tetany64 HP:0001281
35 basal ganglia calcification64 HP:0002135
36 hypokalemia64 HP:0002900
37 muscle cramps64 HP:0003394
38 short stature64 HP:0004322
39 abnormal renal physiology64 HP:0012211

UMLS symptoms related to Hypocalcemia, Autosomal Dominant:


muscle cramp, seizures, carpopedal spasm

MGI Mouse Phenotypes related to Hypocalcemia, Autosomal Dominant according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.5CASR, GNA11, GRM1, PRKAR1A
2MP:00053799.2CASR, GCM2, GNA11, PRKAR1A, VDR
3MP:00053829.0GCM2, GNA11, PRKAR1A, TRPM6, VDR
4MP:00053699.0CASR, GNA11, GRM1, PRKAR1A, VDR
5MP:00053678.9CASR, GCM2, GNA11, GRM1, VDR
6MP:00053768.0CASR, GCM2, GNA11, GRM1, PRKAR1A, TRPM6
7MP:00107688.0CASR, GCM2, GNA11, GRM1, PRKAR1A, TRPM6
8MP:00053907.2CASR, GCM2, GNA11, GRM1, PRKAR1A, TRPM6

Drugs & Therapeutics for Hypocalcemia, Autosomal Dominant

About this section

Drugs for Hypocalcemia, Autosomal Dominant (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 173)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
FoscarnetapprovedPhase 43363585-09-1, 4428-95-93415
Synonyms:
1nki
34156-56-4
4428-95-9
4428-95-9 (Parent)
63585-09-1
63585-09-1 (tri-hydrochloride salt)
79510_FLUKA
A 29622
A-29622
AC-2085
AC1L1FVT
AC1L2C37
AC1L5400
AC1NB82R
AC1Q1UNV
AR-1L5079
Ambap63585-09-1
BSPBio_003067
C06456
CHEBI:127780
CHEBI:141644
CHEBI:60269
CHEMBL666
CHEMBL754
CID169569
CID3415
CID44561
Carboxyphosphonic acid
D00579
D02267
DB00529
DRG-0017
Dihydroxyphosphinecarboxylic acid oxide
Dihydroxyphosphinecarboxylic acid oxide and MSL, neutralizing monoclonal antibody
Dihydroxyphosphinecarboxylic acid oxide trisodium salt
Dihydroxyphosphinecarboxylic acid oxide trisodium salt hexahydrate
DivK1c_000915
EHB 776
EHB-776
FOSCARNET SODIUM
Formic acid, phosphono-, trisodium salt, hexahydrate
Forscarnet sodium
Foscarmet
Foscarnet & IFN-.ALPHA.
Foscarnet sodico
Foscarnet sodico [Spanish]
Foscarnet sodique
Foscarnet sodique [French]
Foscarnet sodique [INN-French]
Foscarnet sodium (USAN/INN)
Foscarnet sodium [USAN:INN:BAN]
Foscarnet sodium hydrate
Foscarnet sodium hydrate (JAN)
Foscarneto sodico
Foscarneto sodico [INN-Spanish]
Foscarnetum natricum
Foscarnetum natricum [INN-Latin]
Foscarnetum natricum [Latin]
Foscavir
Foscavir (TN)
HMS1921D18
HMS2092N15
HMS502N17
 
HS-0008
IDI1_000915
KBio1_000915
KBio2_001839
KBio2_004407
KBio2_006975
KBio3_002567
KBioGR_001419
KBioSS_001839
LS-105952
LS-105953
LS-183979
LS-187063
LS-187793
MSL & PFA
MolPort-003-665-560
MolPort-003-895-968
NCGC00094941-01
NCGC00094941-02
NChemBio.2007.9-comp7
NINDS_000915
NSC313410
P6801_ALDRICH
P6801_SIGMA
PFA & rIFN.alpha.A
Phgosphonocarboxylic acid
Phosphinecarboxylic acid, dihydroxy-, oxide
Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt
Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt, hexahydrate
Phosphonoformate
Phosphonoformate(trisodium) & Recombinant Alpha-A Interferon
Phosphonoformic acid
Phosphonoformic acid & IFN-.ALPHA.
Phosphonoformic acid trisodium salt hexahydrate
Phosphonoformic acid, trisodium salt
Phosphonoformic acid, trisodium salt, hexahydrate
Phosphonomethanoic acid
Prestwick_1024
SPBio_000735
SPECTRUM1502019
Sodium phosphonoformate tribasic hexahydrate
Spectrum2_000668
Spectrum3_001484
Spectrum4_000840
Spectrum5_000932
Spectrum_001359
Triapten
Trisodium carboxyphosphate
Trisodium phosphonoformate
Trisodium phosphonoformate hexahydrate
Trisodium phosphonoformte hexahydrate
UNII-364P9RVW4X
UNII-964YS0OOG1
Virudin
dihydroxyphosphanecarboxylic acid oxide
foscarnet
foscarnet sodium hexahydrate
phosphonomethanoic acid
sodium dioxidophosphanecarboxylate oxide hydrate(3:1:6)
trisodium carboxyphosphate (anhydrous)
trisodium dioxidophosphanecarboxylate oxide
trisodium dioxidophosphinecarboxylate oxide
trisodium phosphonatoformate
trisodium phosphonatoformate hexahydrate
trisodium phosphonoformate (anhydrous)
2
Magnesium Sulfateapproved, vet_approvedPhase 41797487-88-924083
Synonyms:
(C10-C16) Alkylalcohol sulfuric acid, magnesium salt
00627_FLUKA
10028-26-9
10034-99-8 (heptahydrate)
13143_RIEDEL
13143_SIAL
139939-75-6
18939-43-0
203726_ALDRICH
208094_SIAL
34276_FLUKA
34276_RIEDEL
38146_FLUKA
38146_RIEDEL
63126_FLUKA
63136_FLUKA
63136_SIAL
63139_FLUKA
63139_SIAL
68081-97-0
7487-88-9
AC1L2N76
AC1LAX36
AC1Q1U66
AI3-02029
Bitter salt
C10-C16 Alkyl alcohol sulfuric acid magnesium salt
CCRIS 8411
CHEBI:32599
CID24083
CPD0-2390
Caswell No. 534
D008278
DB00653
EINECS 231-298-2
EINECS 233-073-4
EINECS 242-691-3
EINECS 268-365-0
EPA Pesticide Chemical Code 050503
Epsom salt
HSDB 664
Hair salt
Heptahydrate Magnesium Sulfate
Kieserite [as monohydrate]
LS-88605
M2643_SIGMA
M3409_SIGMA
 
M7506_SIAL
M8150_SIGMA
MAGNESIUM SULFATE
Magnesium Sulfate In Plastic Container
Magnesium Sulfate, Heptahydrate
Magnesium Sulphate Hydrate
Magnesium bisulfate
Magnesium hydrogensulphate
Magnesium sulfate
Magnesium sulfate (1:1)
Magnesium sulfate anhydrous
Magnesium sulfate dried
Magnesium sulfate heptahydrate
Magnesium sulfate hexahydrate
Magnesium sulfate in dextrose 5% in plastic container
Magnesium sulfate solution
Magnesium sulphate
Magnesium sulphate anhydrous
Magnesium sulphate dried
Magnesium sulphate heptahydrate
Magnesium(II) sulfate
Magnesium(ii) sulfate
Magnesiumsulfat
MgSO4
MolPort-003-925-000
NSC 146179
OT-S
OT-S (drying agent)
SDA 15-062-07
Sal Angalis
Sal De sedlitz
Sal amarum
Sal anglicum
Sal catharticum
Sal seidlitense
Salts of england
Sel d'angleterre
Sulfate, Magnesium
Sulfuric acid magnesium salt
Sulfuric acid magnesium salt (1:1)
Sulfuric acid magnesium salt (VAN)
Sulfuric acid, C10-16 alkyl ester, magnesium salt
Sulfuric acid, magnesium salt
Sulfuric acid, magnesium salt (1:1)
Sulfuric acid, mono-C10-16-alkyl esters, magnesium salts
Tomix OT
UNII-DE08037SAB
UNII-ML30MJ2U7I
magnesium(2+) ion sulfate
3
Heparinapproved, investigationalPhase 48489005-49-6772, 46507594
Synonyms:
101921-26-0
102-94-3
102785-31-9
104521-37-1
11078-24-3
11129-39-8
12656-11-0
2-o-sulfohexopyranuronosyl-(1->4)-2-deoxy-3-o-sulfo-2-(sulfoamino)hexopyranosyl-(1->4)-2-o-sulfohexopyranuronosyl-(1->4)-2-acetamido-2-deoxy-6-o-sulfohexopyranose
37324-73-5
6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
9041-08-1
9045-22-1
9075-96-1
913079-23-9
91449-79-5
AC1L19ZN
AC1L1ROY
ALFA 87-120
ALFA 87-163
ALFA 87-198
ALFA 87-81
ALFA 88-247
AR-1E4539
Allocinnamic acid
Ardeparin
Ardeparin sodium
Arteven
Bemiparin
Bemiparin sodium
CID772
CID8784
CY 216
Calciparine
Certoparin
Clexane
Clivarin
Clivarine
Cy 222
D006495
D017984
DB00407
DB01225
Dalteparin
Dalteparin sodium
Depo-Heparin
EINECS 232-681-7
EMT 966
EMT 967
EMT-966
EMT-967
EMT966
EMT967
Enoxaparin
Enoxaparin sodium
Enoxaparine
Eparina
Eparina [DCIT]
FR 860
Fluxum
Fragmin A
Fragmin B
Fragmin IV
Fraxiparin
H 2149
HSDB 3094
Hed-heparin
Hep Flush Kit in plastic container
Hep-Lock
Hep-Lock U/P
Hep-lock
Heparin
Heparin CY 216
Heparin Lock Flush
Heparin Lock Flush in plastic container
Heparin Lock Flush preservative free
Heparin Lock Flush preservative free in plastic container
Heparin Sodium
Heparin natrium
Heparin sodium
Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 1,000 units in dextrose 5% in plastic container
Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 10,000 units in dextrose 5%
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 10,000 units in sodium chloride 0.45%
Heparin sodium 10,000 units in sodium chloride 0.9%
Heparin sodium 12,500 units in dextrose 5%
Heparin sodium 12,500 units in dextrose 5% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.9%
Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 2,000 units in dextrose 5% in plastic container
Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 20,000 units and dextrose 5% in plastic container
Heparin sodium 20,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units and dextrose 5% in plastic container
 
Heparin sodium 25,000 units in dextrose 5%
Heparin sodium 25,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units in dextrose 5% in plastic container
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sodium 5,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container
Heparin sodium in plastic container
Heparin sodium preservative Free
Heparin sulfate
Heparin sulphate
Heparin, Low Molecular Weight
Heparin, Low-Molecular-Weight
Heparin, sodium salt
Heparina
Heparina [INN-Spanish]
Heparinate
Heparine
Heparine [INN-French]
Heparinic acid
Heparinsodiumsalt
Heparinum
Heparinum [INN-Latin]
Heparinum natricum
Hepathrom
Hepflush-10
Inno-Hep
Innohep
Isocinnamic acid
KB 101
Kabi 2165
LHN 1
LMWH
Lioton 1000
Lipo-hepin
Liquaemin
Liquaemin Lock Flush
Liquaemin Sodium
Liquaemin sodium preservative free
Liquemin
Logiparin
Lovenox
Lovenox HP
Low Molecular Weight Heparin
Low molecular weight heparin
Low molecular weight heparin sodium
Low-Molecular-Weight Heparin
Minolteparin sodium
MolPort-003-760-257
Multiparin
NSC174025
Nadroparin
Nadroparine
Novoheparin
OP 386
OP 622
Octaparin
PK 10,169
PK-10,169
PK-10169
PK10,169
PK10169
Pabyrin
Panheprin
Parnaparin
Parnaparin sodium
Parvoparin
Pularin
Reviparin
Reviparin sodium
Ro 11
Sandoparin
Sodium acid heparin
Sodium heparin
Sodium heparinate
Subeparin
Sublingula
Thromboliquine
Tinzaparin
Tinzaparin sodium
Triofiban
UNII-12M44VTJ7B
UNII-3S182ET3UA
UNII-E47C0NF7LV
UNII-T2410KM04A
UNII-ZZ45AB24CA
Unfractionated heparin
Vetren
Vitrum AB
WY 90493RD
alpha-Heparin
cis-.beta.-Carboxystyrene
cis-Cinnamic acid
enoxaparin
heparin
4
AlendronateapprovedPhase 4162121268-17-5, 66376-36-12088
Synonyms:
(4-Amino-1-hydroxybutylidene)bisphosphonic acid
(4-Amino-1-hydroxybutylidene)diphosphonic acid
(4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid
(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)
(4-amino-1-hydroxybutylidene)bisphosphonic acid
121268-17-5 (mono-hydrochloride salt, trihydrate)
1yhm
4-Amino-1-hydroxybutane-1,1-diphosphonate
4-Amino-1-hydroxybutane-1,1-diphosphonic Acid
4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid)
4-Amino-1-hydroxybutylidene-1,1-bisphosphonate
4-amino-1-hydroxybutane-1,1-diphosphonic acid
66376-36-1
ABDP
AC1L1CW3
AKOS001015793
ALENDRONATE SODIUM
ALENDRONIC ACID
Acide Alendronique
Acide Alendronique [INN-French]
Acide alendronique
Acide alendronique [INN-French]
Acido Alendronico
Acido Alendronico [INN-Spanish]
Acido alendronico
Acido alendronico [INN-Spanish]
Acidum Alendronicum
Acidum Alendronicum [INN-Latin]
Acidum alendronicum
Acidum alendronicum [INN-Latin]
Adronat
 
Alendronate
Alendronate Sodium
Alendronate sodium hydrate
Alendronic acid
Alendronic acid (INN)
Alendronic acid [INN:BAN]
Alendros
Arendal
BIDD:GT0180
C07752
CHEBI:2567
CHEMBL870
CID2088
D07119
DB00630
Fosamax
Fosamax Plus D
HSCI1_000337
LS-106421
MK 217
MK-217
MolPort-000-421-410
NCGC00096054-01
NCGC00096054-03
NCGC00096054-04
Onclast
Oprea1_422906
Phosphonic acid, (4-amino-1-hydroxybutylidene)bis
SPECTRUM1505166
ST50036159
UNII-X1J18R4W8P
alendronate
bisphosphonate, 65
5
Zoledronic acidapprovedPhase 4, Phase 1294118072-93-868740
Synonyms:
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate
(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
118072-93-8
2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
AC-1092
AC1L2ACJ
AC1Q6RN3
AKOS005145739
Aclasta
Anhydrous Zoledronic Acid
BIDD:GT0292
BIDD:PXR0134
Bio-0112
Bisphosphonate 3
C088658
CGP 42'446
CGP 42446
CGP 42446A
CGP-42'446
CGP-42446
CHEBI:46557
CHEMBL924
CID68740
D08689
DB00399
 
FT-0082657
HMS2089O09
I06-0710
KS-1132
LS-181815
MolPort-002-885-874
MolPort-003-850-890
NCGC00159521-02
NCGC00159521-03
NSC721517
Novartis brand of zoledronic acid
Reclast
Reclast (TN)
S00092
S1314_Selleck
UNII-70HZ18PH24
ZOL
Zol
Zoledronate
Zoledronic Acid Anhydrous
Zoledronic Acid, Anhydrous
Zoledronic acid
Zoledronic acid (INN)
Zoledronic acid [USAN:INN]
Zometa
Zometa (Novartis)
Zometa (TN)
Zometa Concentrate
Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
6
Betamethasoneapproved, vet_approvedPhase 4195378-44-99782
Synonyms:
.beta.-Methasone
.beta.-Methasone alcohol
1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol
16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione
16β-Methyl-1,4-pregnadiene-9α-fluoro-11β,17α,21-triol-3,20-dione
24024-03-1
34166_FLUKA
34166_RIEDEL
378-44-9
4-08-00-03501 (Beilstein Handbook Reference)
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione
9-Fluoro-16.beta.-methylprednisolone
9-Fluoro-16beta-methylprednisolone
9-Fluoro-16β-methylprednisolone
9-alpha-Fluoro-16-beta-methylprednisolone
9.alpha.-Fluoro-16.beta.-methylprednisolone
9alpha-Fluoro-16 beta-methyl-prednisolone
9alpha-Fluoro-16beta-methylprednisolone
9α-Fluoro-16β-methylprednisolone
AC1L1EYE
AC1L1TT4
AC1Q5HJZ
AKOS001582690
AR-1A7284
AR-1H5595
B1837
B7005_SIAL
B7005_SIGMA
B9675_SIAL
BIDD:PXR0047
BPBio1_000533
BRD-A35108200-001-04-7
BRD-K39188321-001-03-9
BRN 3176546
BSPBio_000483
Bebate
Becort
Bedifos
Betacorlan
Betacortril
Betadexamethasone
Betafluorene
Betamamallet
Betametasona
Betametasona [INN-Spanish]
Betametasone
Betametasone [DCIT]
Betamethasone
Betamethasone (JP15/USP/INN)
Betamethasone Base
Betamethasone Valearate
Betamethasone [USAN:BAN:INN:JAN]
Betamethasone [USAN:INN:BAN:JAN]
Betamethasone alcohol
Betamethasone cream
Betamethasonum
Betamethasonum [INN-Latin]
Betamethasonvalerat Mikron
Betamethazone
Betapredol
Betasolon
Betnelan
 
Betsolan
C22H29FO5
CHEBI:3077
CHEMBL632
CID3003
CID9782
CPD000339803
Celestene
Celeston
Celestona
Celestone
Celestone Syrup and Tablets
Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone
Cellestoderm
Cidoten
D00244
D1961
DB00443
Desacort-Beta
EINECS 206-825-4
Flubenisolone
HMS1569I05
HSDB 3015
Hormezon
I06-0121
KST-1A3042
LS-118466
LT00441022
Luxiq
Luxiqo
MLS-0310139.0001
MLS000686794
MLS000859943
MLS001066413
MLS001332616
MLS002153244
Methazon
MolPort-003-845-025
MolPort-007-981-051
NCGC00164401-01
NCGC00164401-02
NSC 39470
NSC-39470
NSC39470
Prestwick0_000362
Prestwick1_000362
Prestwick2_000362
Prestwick3_000362
Prestwick_703
Rinderon
Rinderon (TN)
Rinderon A
S1500_Selleck
SAM002589959
SCH 4831
SCH-4831
SMP1_000043
SMR000058601
SMR000339803
SPBio_002404
UNII-9842X06Q6M
Valisone
Visubeta
ZINC03876136
beta-Methasone
beta-Methasone alcohol
betamethasone
7
Cholecalciferolapproved, nutraceuticalPhase 4, Phase 2, Phase 387567-97-06221, 10883523, 5280795
Synonyms:
()-Vitamin D3
(+)-Vitamin D3
(+)-vitamin D3
(1S,3Z)-3-[(2e)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-Secocholesta-5,7,10-trien-3-ol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol
1406-16-2
25(OH)D
3-beta,Z,7E-9,10-Secocholestr-5,7,10(19)-trien-3-ol
47763_SUPELCO
57651-82-8
67-97-0
7-Dehydrocholesterol activated
7-Dehydrocholesterol, Activated
7-Dehydrocholesterol, irradiated
7-Dehydrocholestrol, activated
8024-19-9
8050-67-7
89193_FLUKA
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol
9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol
9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
9,10-Secocholesta-5,7,10(19)-trien-3-ol
9,10-Secocholesta-5,7,10-trien-3-ol
AB1002422
AC-11697
AC1L1ECK
AC1L1M23
AC1LU7IZ
AC1NQXLN
AC1NR2UO
AC1NR2UR
AC1NR2UU
AC1NS4AJ
AC1NSHJX
AC1O5EOF
AC1O7GAV
AC1O7GQ3
AC1O8FEU
AC1O8PWJ
AC1OF2GI
AC1OF2GL
AC1OIEW5
AC1OIEWB
ACon1_001997
Activated 7-dehydrocholesterol
Arachitol
BPBio1_000460
BSPBio_000418
BSPBio_002408
Bio-0845
C05443
C1357_SIAL
C27H44O
C9756_SIGMA
C9774_SIAL
CAS-67-97-0
CC
CCRIS 5813
CCRIS 6286
CHEBI:283119
CHEBI:28940
CHEMBL1042
CHEMBL432780
CID10000117
CID10045875
CID10340013
CID10883523
CID10894379
CID11014566
CID11025493
CID11058152
CID11463269
CID1548921
CID2735
CID5280795
CID5283710
CID5283711
CID5283712
CID5353527
CID5363362
CID6221
CID6432644
CID6604201
CID6604662
CID6708595
CID6713938
CID6992015
CID6992016
CID7067439
CID7067440
CID7251172
CID7251174
CID9821465
Calciol
Cholecalciferol
Cholecalciferol (D3)
Cholecalciferol (JP15/USP)
Cholecalciferol D3
Cholecalciferol [USAN:BAN:JAN]
Cholecalciferol, D3
Cholecalciferolum
Colecalciferol
 
Colecalciferol (INN)
Colecalciferolo
Colecalciferolo [DCIT]
Colecalciferolum
Colecalciferolum [INN-Latin]
Colecalcipherol
D00188
D3-Vicotrat
D3-Vigantol
DB00169
Delsterol
Delta-D
Delta-D (TN)
Deparal
Devaron
DivK1c_006276
Duphafral D3 1000
EINECS 200-673-2
EINECS 215-797-2
EPA Pesticide Chemical Code 202901
Ebivit
FeraCol
Granuvit D3
HMS1569E20
HMS2092M12
HSDB 820
I05-0041
Irradiated 7-dehydrocholesterol
KBio1_001220
KBio2_001643
KBio2_004211
KBio2_006779
KBio3_001628
KBioGR_001602
KBioSS_001643
LMST03020001
LMST03020219
LMST03020220
LMST03020221
LS-1570
LS-825
LT00244775
MEGxm0_000458
Micro-dee
MolPort-001-740-051
MolPort-001-785-972
MolPort-003-666-021
MolPort-004-946-964
NCGC00016301-01
NCGC00017328-01
NCGC00091072-01
NCGC00142511-01
NCGC00159331-02
NCGC00159331-04
NCGC00178668-01
NCGC00179565-01
NCGC00179565-02
NEO Dohyfral D3
NSC 375571
NSC-375571
NSC375571
Oleovitamin D3
Prestwick0_000429
Prestwick1_000429
Prestwick2_000429
Prestwick3_000429
Prestwick_63
Provitamine
Provitina
Quintox
Rampage
Ricketon
SMP1_000068
SPBio_001298
SPBio_002357
SR-05000001559
SR-05000001559-3
ST057172
SpecPlus_000180
Spectrum2_001369
Spectrum3_000764
Spectrum4_001201
Spectrum_001163
TNP00266
Trivitan
UNII-1C6V77QF41
UPCMLD-DP152
UPCMLD-DP152:001
VITAMIN D
VITAMIN D3 POWDER
VITAMIN_D3
Vi-De3
Vi-de-3-hydrosol
VidDe-3-hydrosol
Videkhol
Vigantol
Vigorsan
Vitamin D-3
Vitamin D3
Vitamin D3 emulsifiable
Vitinc Dan-Dee-3
ZINC04474460
ZINC04492874
ZINC04492875
ZINC04492876
ZINC04492878
bmse000507
cholecalciferol
colecalciferolum
vitamin d-3
8
Ergocalciferolapproved, nutraceuticalPhase 4, Phase 2, Phase 3128150-14-65280793
Synonyms:
'Ergosterol irradiated'
(+)-Vitamin D2
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7e,22e)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,Secoergosta-5,7,10(19)-ol
31316-19-5
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3aH)-indanylidene]ethylidene]-Cyclohexanol
47768_SUPELCO
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
BPBio1_000418
BSPBio_000380
BSPBio_001974
Buco-D
C05441
C28H44O
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
Calciferolum
Calciferon 2
Condacaps
Condocaps
Condol
Crtron
Crystallina
D-Arthin
D-Tracetten
D00187
DB00153
Daral
Davitamon D
Davitin
De-rat concentrate
Decaps
Dee-Osterol
Dee-Ron
Dee-Ronal
Dee-Roual
Deltalin
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
E5750_SIGMA
EINECS 200-014-9
Ercalciol
Ergocalciferol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
 
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Haliver
Hi-Deratol
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
MLS001332467
MLS001332468
Metadee
Mina D2
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
NSC 62792
NSC62792
Novovitamin-D
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick3_000420
Prestwick_554
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
SMR000857106
SPECTRUM1500276
ST057150
STOCK1N-53397
Shock-ferol
Shock-ferol sterogyl
Sorex C.R
Sorex C.R.
Spectrum5_000666
Sterogyl
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
VITAMIN_D2
Vigantol
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in Oil
Vitamin D2
Vitamin- D2
Vitamin-?D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
beta-Ol
bmse000510
component of Geltabs Vitamin D
delta-Arthin
delta-Tracetten
ergocalciferol
vitamin d-2
9
Alfacalcidolapproved, nutraceuticalPhase 4, Phase 26141294-56-85282181
Synonyms:
(5Z,7e)-9,10-Seco-5,7,10(19)-cholestatrien-1alpha,3beta-diol
1-Hydroxycholecalciferol
1-hydroxycholecalciferol
1alpha-Hydroxy-vitamin D3
 
1alpha-hydroxycholecalciferol
1alpha-hydroxyvitamin D3
9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta-diol
Alfacalcidolum
Alsiodol
10
Phosphonoacetic AcidexperimentalPhase 4334408-78-0546
Synonyms:
Carboxymethanephosphonate
Carboxymethanephosphonic acid
Disodium carboxymethylphosphonate
Disodium phosphonoacetate
Disodium phosphonoacetate monohydrate
Fosfonet
Fosfonet sodium
 
Fosfonoacetate
Fosfonoacetic acid
Lopac-P-6909
PAE
PPA
Phosphonacetate
Phosphonacetic acid
Phosphonoacetate
Phosphonoacetic acid
11Cinacalcet HydrochloridePhase 4, Phase 2, Phase 371
12Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 113180
13Calcimimetic AgentsPhase 4, Phase 2, Phase 371
14Calcium, DietaryPhase 4, Phase 3, Phase 2, Phase 15713
15HormonesPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 114415
16VaccinesPhase 4, Phase 3, Phase 2, Phase 16611
17Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 113168
18vitamin dPhase 4, Phase 2, Phase 3, Phase 11724
19Trace ElementsPhase 4, Phase 2, Phase 36001
20MicronutrientsPhase 4, Phase 2, Phase 36001
21VitaminsPhase 4, Phase 2, Phase 3, Phase 15282
22Bone Density Conservation AgentsPhase 4, Phase 2, Phase 3, Phase 13376
23Pharmaceutical SolutionsPhase 4, Phase 2, Phase 3, Phase 18192
24ErgocalciferolsPhase 4, Phase 2, Phase 31281
25Dialysis SolutionsPhase 4175
26ImmunoglobulinsPhase 4, Phase 1, Phase 26394
27AntibodiesPhase 4, Phase 1, Phase 26394
28HydroxycholecalciferolsPhase 4, Phase 2129
29Chelating AgentsPhase 4, Phase 31423
301 alpha-hydroxyergocalciferolPhase 425
31Fibrinolytic AgentsPhase 42388
32Nucleic Acid Synthesis InhibitorsPhase 44962
33Anti-Arrhythmia AgentsPhase 43093
34AnticonvulsantsPhase 42695
35Anti-Infective AgentsPhase 4, Phase 2, Phase 122062
36AnestheticsPhase 4, Phase 2, Phase 19596
37AnalgesicsPhase 4, Phase 1, Phase 211733
38DiphosphonatesPhase 4450
39Hypoglycemic AgentsPhase 45896
40calcium heparinPhase 4848
41Anti-Retroviral AgentsPhase 43296
42Antiviral AgentsPhase 49967
43Tocolytic AgentsPhase 4739
44AnticoagulantsPhase 42623
45Peripheral Nervous System AgentsPhase 4, Phase 1, Phase 223689
46Reverse Transcriptase InhibitorsPhase 41913
47calcium channel blockersPhase 41985
48Central Nervous System DepressantsPhase 413403
49Betamethasone-17,21-dipropionatePhase 4195
50Betamethasone ValeratePhase 41952152-44-5

Interventional clinical trials:

(show top 50)    (show all 127)
idNameStatusNCT IDPhase
1An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine BoosterUnknown statusNCT00870350Phase 4
2Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast®CompletedNCT00668200Phase 4
3Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot StudyCompletedNCT00002146Phase 4
4Citrate-based Regional Anticoagulation Versus Heparin for Continuous Renal Replacement TherapyCompletedNCT01269112Phase 4
5Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin DCompletedNCT00977080Phase 4
6Study of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney DiseaseCompletedNCT00395382Phase 4
7Regulatory Post-Marketing Surveillance Study for TETRAXIM™CompletedNCT01437423Phase 4
8Post Marketing Surveillance for ADACEL™ in South KoreaCompletedNCT01137435Phase 4
9Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™CompletedNCT00802867Phase 4
10Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap VaccineCompletedNCT00777257Phase 4
11Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous DoseCompletedNCT00712959Phase 4
12Phase IV Interchangeability Study of a Liquid Pentavalent Combination VaccineCompletedNCT00674908Phase 4
13Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured TdCompletedNCT00601835Phase 4
14Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio VaccineCompletedNCT00514059Phase 4
15A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and OlderCompletedNCT00457249Phase 4
16Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® VaccineCompletedNCT00347958Phase 4
17Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®CompletedNCT00319553Phase 4
18Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis VaccineCompletedNCT00304265Phase 4
19US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal DiseaseCompletedNCT00282295Phase 4
20Steroids in the Postoperative Transient Hypoparathyroidism Total ThyroidectomyRecruitingNCT02652884Phase 4
21Vitamin D Deficiency and Postoperative HypocalcemiaActive, not recruitingNCT01632514Phase 4
22Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective LevelsTerminatedNCT00437671Phase 4
23Glyburide Compared to Insulin in the Management of White's Classification A2 Gestational DiabetesWithdrawnNCT00160485Phase 4
24Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD)Unknown statusNCT01479088Phase 2, Phase 3
25Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to EtelcalcetideCompletedNCT01932970Phase 3
26Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on HemodialysisCompletedNCT01788046Phase 3
27Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on HemodialysisCompletedNCT01785875Phase 3
28Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on HemodialysisCompletedNCT01785849Phase 3
29Prophylactic Central Lymph Node Dissection in Papillary Thyroid MicrocarcinomaCompletedNCT00795782Phase 3
30Use of NPSP558 in the Treatment of HypoparathyroidismCompletedNCT00732615Phase 3
31Effect of Vitamin D Treatment in Primary HyperparathyroidismCompletedNCT00674154Phase 2, Phase 3
32Magnesium Effects in ApheresisCompletedNCT00040235Phase 3
33Study of BK1301 (DTaP Vaccine) as a Booster in AdolescentsCompletedNCT02118961Phase 3
34Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years OldCompletedNCT02089347Phase 3
35Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type BCompletedNCT01362517Phase 3
36Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of AgeCompletedNCT01346293Phase 3
37Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or OlderCompletedNCT01287949Phase 3
38Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years OldCompletedNCT01249183Phase 3
39Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended VaccineCompletedNCT00662870Phase 3
40REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-Old ChildrenCompletedNCT00447525Phase 3
41Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and ToddlersCompletedNCT00343421Phase 3
42Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in InfantsCompletedNCT00287092Phase 3
43Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 WeeksRecruitingNCT02051218Phase 3
44Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruSRecruitingNCT02458183Phase 3
45HEXT (Hypo EXTended): Effect of PTH on Skeleton in HypoparathyroidismActive, not recruitingNCT01199614Phase 3
46Comparison of Total Parathyroidectomy With and Without AutotransplantationNot yet recruitingNCT02536287Phase 3
47RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen PlasmaTerminatedNCT01545635Phase 3
48Interest of Using Balanced Fluid for Infusion at the Early Phase of an Acute Cranial Trauma for Limiting Hyperchloremic AcidosisTerminatedNCT00847977Phase 3
49Safety and Tolerability Study of MCI-196TerminatedNCT01818687Phase 3
50Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed PatientsTerminatedNCT01011699Phase 3

Search NIH Clinical Center for Hypocalcemia, Autosomal Dominant

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: hypocalcemia

Genetic Tests for Hypocalcemia, Autosomal Dominant

About this section

Genetic tests related to Hypocalcemia, Autosomal Dominant:

id Genetic test Affiliating Genes
1 Hypocalcemia, Autosomal Dominant 127
2 Hypocalcemia, Autosomal Dominant, with Bartter Syndrome27
3 Autosomal Dominant Hypocalcemia27 24 CASR

Anatomical Context for Hypocalcemia, Autosomal Dominant

About this section

MalaCards organs/tissues related to Hypocalcemia, Autosomal Dominant:

36
Kidney, Skin, Liver, Bone, Heart

Publications for Hypocalcemia, Autosomal Dominant

About this section

Variations for Hypocalcemia, Autosomal Dominant

About this section

UniProtKB/Swiss-Prot genetic disease variations for Hypocalcemia, Autosomal Dominant:

70 (show all 34)
id Symbol AA change Variation ID SNP ID
1CASRp.Ala116ThrVAR_003588
2CASRp.Glu127AlaVAR_003589
3CASRp.Gln681HisVAR_003598
4CASRp.Phe806SerVAR_003600
5CASRp.Leu616ValVAR_015414
6CASRp.Glu767LysVAR_021019
7CASRp.Lys47AsnVAR_058050
8CASRp.Asn118LysVAR_058051
9CASRp.Leu125ProVAR_058052
10CASRp.Phe128LeuVAR_058053
11CASRp.Cys131TrpVAR_058054
12CASRp.Thr151MetVAR_058055
13CASRp.Glu191LysVAR_058058
14CASRp.Glu604LysVAR_058070
15CASRp.Phe612SerVAR_058071
16CASRp.Leu727GlnVAR_058075
17CASRp.Leu773ArgVAR_058078
18CASRp.Phe788CysVAR_058079
19CASRp.Phe788LeuVAR_058080
20CASRp.Ser820PheVAR_058081
21CASRp.Ala843GluVAR_058082
22CASRp.Ser122CysVAR_078145
23CASRp.Leu125PheVAR_078146
24CASRp.Cys129ArgVAR_078147
25CASRp.Pro136LeuVAR_078148
26CASRp.Pro221LeuVAR_078157
27CASRp.Glu228LysVAR_078159
28CASRp.Pro569HisVAR_078165
29CASRp.Gln681ArgVAR_078171
30CASRp.Asn802IleVAR_078176
31CASRp.Gly830SerVAR_078179
32CASRp.Phe832LeuVAR_078180
33CASRp.Phe832SerVAR_078181
34CASRp.Ile839ThrVAR_078182

Clinvar genetic disease variations for Hypocalcemia, Autosomal Dominant:

5 (show all 22)
id Gene Variation Type Significance SNP ID Assembly Location
1CASRNM_ 000388.3(CASR): c.2482A> C (p.Thr828Pro)SNVLikely pathogenicrs794729230GRCh38Chr 3, 122284436: 122284436
2CASRNM_ 000388.3(CASR): c.662C> T (p.Pro221Leu)SNVPathogenicrs397514728GRCh37Chr 3, 121980544: 121980544
3CASRNM_ 000388.3(CASR): c.380A> C (p.Glu127Ala)SNVPathogenicrs121909260GRCh37Chr 3, 121976122: 121976122
4CASRNM_ 000388.3(CASR): c.2043G> T (p.Gln681His)SNVPathogenicrs121909261GRCh37Chr 3, 122002844: 122002844
5CASRNM_ 000388.3(CASR): c.346G> A (p.Ala116Thr)SNVPathogenicrs104893691GRCh37Chr 3, 121976088: 121976088
6CASRNM_ 000388.3(CASR): c.2417T> C (p.Phe806Ser)SNVPathogenicrs104893693GRCh37Chr 3, 122003218: 122003218
7CASRNM_ 000388.3(CASR): c.452C> T (p.Thr151Met)SNVPathogenicrs104893694GRCh37Chr 3, 121976194: 121976194
8CASRNM_ 000388.3(CASR): c.354C> A (p.Asn118Lys)SNVPathogenicrs104893695GRCh37Chr 3, 121976096: 121976096
9CASRNM_ 000388.3(CASR): c.382T> C (p.Phe128Leu)SNVPathogenicrs104893696GRCh37Chr 3, 121976124: 121976124
10CASRNM_ 000388.3(CASR): c.571G> A (p.Glu191Lys)SNVPathogenicrs104893697GRCh37Chr 3, 121980453: 121980453
11CASRNM_ 000388.3(CASR): c.1835T> C (p.Phe612Ser)SNVPathogenicrs104893698GRCh37Chr 3, 122002636: 122002636
12CASRNM_ 000388.3(CASR): c.2318T> G (p.Leu773Arg)SNVPathogenicrs104893699GRCh37Chr 3, 122003119: 122003119
13CASRNM_ 000388.3(CASR): c.2363T> G (p.Phe788Cys)SNVPathogenicrs104893701GRCh37Chr 3, 122003164: 122003164
14CASRNM_ 000388.3(CASR): c.141A> C (p.Lys47Asn)SNVPathogenicrs104893702GRCh37Chr 3, 121973177: 121973177
15CASRNM_ 000388.3(CASR): c.1846C> G (p.Leu616Val)SNVPathogenicrs104893703GRCh37Chr 3, 122002647: 122002647
16CASRNM_ 000388.3(CASR): c.2682_ 3224del543 (p.Ser895_ Val1075del)deletionPathogenicGRCh38Chr 3, 122284636: 122285178
17CASRNM_ 000388.3(CASR): c.2528C> A (p.Ala843Glu)SNVPathogenicrs104893706GRCh37Chr 3, 122003329: 122003329
18CASRNM_ 000388.3(CASR): c.374T> C (p.Leu125Pro)SNVPathogenicrs104893708GRCh37Chr 3, 121976116: 121976116
19CASRNM_ 000388.3(CASR): c.2459C> T (p.Ser820Phe)SNVPathogenicrs104893710GRCh37Chr 3, 122003260: 122003260
20CASRNM_ 000388.3(CASR): c.2362T> C (p.Phe788Leu)SNVPathogenicrs104893711GRCh37Chr 3, 122003163: 122003163
21CASRNM_ 000388.3(CASR): c.1810G> A (p.Glu604Lys)SNVPathogenicrs104893712GRCh37Chr 3, 122002611: 122002611
22CASRNM_ 000388.3(CASR): c.2180T> A (p.Leu727Gln)SNVPathogenicrs104893718GRCh37Chr 3, 122002981: 122002981

Expression for genes affiliated with Hypocalcemia, Autosomal Dominant

About this section
Search GEO for disease gene expression data for Hypocalcemia, Autosomal Dominant.

Pathways for genes affiliated with Hypocalcemia, Autosomal Dominant

About this section

GO Terms for genes affiliated with Hypocalcemia, Autosomal Dominant

About this section

Cellular components related to Hypocalcemia, Autosomal Dominant according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1neuron projectionGO:00430058.7CALCA, CASR, GRM1

Biological processes related to Hypocalcemia, Autosomal Dominant according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1calcium ion transportGO:00068169.6CASR, TRPM6, VDR
2positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathwayGO:00514829.4CALCA, GRM1
3vasodilationGO:00423119.3CALCA, CASR
4cellular calcium ion homeostasisGO:00068748.8CALCA, CASR, GCM2, VDR

Molecular functions related to Hypocalcemia, Autosomal Dominant according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1signal transducer activityGO:00048719.1CASR, GNA11, GRM1

Sources for Hypocalcemia, Autosomal Dominant

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet